Maxcyte share news
Web12 apr. 2024 · MaxCyte to Report First Quarter 2024 Financial Results on May 10, 2024. ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of … WebMaxCyte, Inc. Common Stock (MXCT) Stock Price, Quote, News & History Nasdaq MXCT MaxCyte, Inc. Common Stock (MXCT) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time...
Maxcyte share news
Did you know?
Web1 dag geleden · MaxCyte to Report First Quarter 2024 Financial Results on May 10, 2024 ROCKVILLE, MD, April 13, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company ... WebMaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the …
WebThe MaxCyte PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 398.00p. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share. WebSee the most recent MaxCyte, Inc. (LSE:MXCT) share price, news, company analysis, and price history from our financial experts.
Web12 apr. 2024 · ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing … Web18 mei 2024 · GAITHERSBURG, Md., May 18, 2024 /PRNewswire/ -- MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the...
Web12 apr. 2024 · Maxcyte To Report First Quarter 2024 Financial Results On May 10, 2024. ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering ...
Web2 dagen geleden · The company’s recent Q4 earnings revealed a beat on EPS and a miss on revenue. However, the company was still able to report year-over-year revenue growth. For the full year, MaxCyte pulled in ... the atrium event venueWeb30 jul. 2024 · GAITHERSBURG, Md., July 29, 2024 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized... the atrium facebookWebMaxCyte is a world-leading provider of cell-engineering platform technologies that drives the next‐generation of cell and gene-editing therapies. The company's technology, which is designed to... the atrium fed squareWeb5 apr. 2024 · Company. MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance cell-based … the atrium facebook cape coral flWeb28 mrt. 2024 · MaxCyte Appoints Douglas Swirsky as Chief Financial Officer Rockville, MD, March 28, 2024 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to … the great american revolution platesWeb12 apr. 2024 · 1 Wall Street analysts have issued 12 month price objectives for MaxCyte's shares. Their MXCT share price forecasts range from GBX 1,060 to GBX 1,060. On … the great american restaurantsWeb1 dag geleden · ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing … the atrium fort collins